 |
市場調査レポート
商品コード
1463298
ジェノタイピングの世界市場規模、シェア、成長分析、タイプ別、用途別 - 産業予測、2024～2031年Global Genotyping Market Size, Share, Growth Analysis, By Type(Microarray, Polymerase Chain Reaction (PCR)), By Application(Pharmaceutical and Biopharmaceutical Companies, Diagnostic Laboratories and Clinics) - Industry Forecast 2024-2031 |
||||||
| ジェノタイピングの世界市場規模、シェア、成長分析、タイプ別、用途別 - 産業予測、2024～2031年 |
|
出版日: 2024年04月08日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のジェノタイピングの市場規模は、2022年に214億3,000万米ドルとなり、予測期間（2024～2031年）のCAGRは22%で、2023年の261億4,000万米ドルから、2031年までには1,283億1,000万米ドルに成長する見通しです。
遺伝子検査ニーズの高まり、個別化医療、ゲノミクス研究の進歩が、世界のジェノタイピング市場の堅調な拡大を後押ししています。遺伝子異常の頻度の増加、病気の早期診断に関する知識の増加、精密医療の進歩は、市場を牽引する理由の一部です。科学と治療の両面で、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、マイクロアレイなどのジェノタイピング技術が頻繁に採用されています。さらに、ジェノタイピング・データをデータ解析やバイオインフォマティクス技術に組み込むことにより、市場は拡大しています。世界のジェノタイピング市場でより大きなシェアを獲得するため、業界の主要な競合企業は製品の革新、遺伝子検査の多様化、戦略的提携に注力しています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要な投資の分析
- 主要な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
ジェノタイピングの世界市場：タイプ別
- 市場概要
- マイクロアレイ
- ポリメラーゼ連鎖反応（PCR）
- シーケンシング
- その他
ジェノタイピングの世界市場：用途別
- 市場概要
- 製薬・バイオ医薬品企業
- 診断研究所・診療所
- 研究機関・学術センター
- その他
ジェノタイピングの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Thermo Fisher Scientific Inc.（United States）
- Illumina, Inc.（United States）
- QIAGEN N.V.（Netherlands）
- Agilent Technologies, Inc.（United States）
- Bio-Rad Laboratories, Inc.（United States）
- F. Hoffmann-La Roche Ltd（Switzerland）
- Danaher Corporation（United States）
- PerkinElmer, Inc.（United States）
- Fluidigm Corporation（United States）
- Eurofins Scientific（Luxembourg）
- Luminex Corporation（United States）
- Pacific Biosciences of California, Inc.（United States）
- Oxford Nanopore Technologies Ltd.（United Kingdom）
- Affymetrix, Inc.（United States）
- Genewiz（United States）
- GENEWIZ Germany GmbH（Germany）
- Bioline Reagents Ltd.（United Kingdom）
- Genomic Health, Inc.（United States）
- Takara Bio Inc.（Japan）
- Agena Bioscience, Inc.（United States）
Global Genotyping Market size was valued at USD 21.43 billion in 2022 and is poised to grow from USD 26.14 billion in 2023 to USD 128.31 billion by 2031, growing at a CAGR of 22% during the forecast period (2024-2031).
The increasing need for genetic testing, personalized medicine, and advances in genomics research are driving the robust expansion of the global genotyping market. Growing frequency of genetic abnormalities, increased knowledge of early illness diagnosis, and advancements in precision medicine are some of the reasons driving the market. In both scientific and therapeutic contexts, genotyping technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarrays are frequently employed. Furthermore, the market is expanding due to the incorporation of genotyping data with data analytics and bioinformatics technologies. To gain a bigger share of the worldwide genotyping market, major competitors in the industry are concentrating on product innovation, diversifying their genetic testing offerings, and forging strategic alliances.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genotyping Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Genotyping Market Segmental Analysis
The Global Genotyping Market is segmented by type, application, and region. Based on type, the market can be segmented into microarray, polymerase chain reaction (pcr), sequencing, and others. Based on application, the market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic laboratories and clinics, research institutes and academic centers, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Genotyping Market
Growing need for customized treatment and the rising incidence of genetic disorders are two major factors propelling the worldwide genotyping industry. Finding genetic variants, mutations, and gene sequences that may be connected to certain illnesses or treatment reactions is made possible in large part by genotyping. Thanks to developments in genomics and our growing knowledge of genetic markers, genotyping now allows for individualized medication choices, diagnosis, and treatments. The growing need for precision medicine techniques and genotyping technologies is fueled by the increased frequency of hereditary illnesses.
Restraints in the Global Genotyping Market
The ethical and privacy issues surrounding genetic testing are a major barrier to the worldwide genotyping market. The availability of a person's genetic information gives rise to worries around potential abuse or misunderstanding of that information. The broad use of genotyping is hampered by concerns about permission, data security, and the possibility of discrimination based on genetic information. In addition, great thought must go into how genetic test findings are interpreted and shared with patients and medical professionals in order to guarantee correct comprehension and the right course of action. It is essential to address these privacy and ethical issues in order to foster involvement, foster confidence, and advance the responsible use of genotyping technology.
Market Trends of the Global Genotyping Market
The growing need for precision healthcare and tailored medication is a major trend in the worldwide genotyping market. In order to detect genetic variants and markers linked to different diseases and treatment responses, genotyping is essential. Researchers and healthcare professionals now have more access to genotyping thanks to advances in genomic technologies and genotyping's declining cost. Based on a person's genetic profile, genotyping enables customized treatment regimens that lead to more focused medicines, better disease management, and better patient outcomes. The potential for customized therapies and our increasing understanding of the genetic underpinnings of disease are what are driving this development. Healthcare is being revolutionized by genotyping because it allows for more targeted and efficient interventions based on each person's own genetic profile.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Genotyping Market by Type
- Market Overview
- Microarray
- Polymerase Chain Reaction (PCR)
- Sequencing
- and Others
Global Genotyping Market by Application
- Market Overview
- Pharmaceutical and Biopharmaceutical Companies
- Diagnostic Laboratories and Clinics
- Research Institutes and Academic Centers
- and Others
Global Genotyping Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Illumina, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fluidigm Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Luminex Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pacific Biosciences of California, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oxford Nanopore Technologies Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Affymetrix, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genewiz (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GENEWIZ Germany GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bioline Reagents Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genomic Health, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takara Bio Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agena Bioscience, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
